Skip to Content


Active Substance: eptotermin alfa
Common Name: eptotermin alfa
ATC Code: M05BC02
Marketing Authorisation Holder: Olympus Biotech International Limited
Active Substance: eptotermin alfa
Status: Withdrawn
Authorisation Date: 2009-02-19
Therapeutic Area: Spondylolisthesis
Pharmacotherapeutic Group: Drugs for treatment of bone diseases

Therapeutic Indication

Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.

The marketing authorisation for Opgenra has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.